# Vaccination Report – 19 October 2021

## 1. Vaccine Implementation

- WHO's Emergency Use Listing(EUL) Vaccines (Last Updated 29 Sep 2021）

| | Manufacturer | Name of Vaccine | NRA of Record | Vaccine type |
|---|---|---|---|---|
| 1 | Pfizer-BioNTech (US) | BNT162b2 | EMA/USFDA | mRNA |
| 2 | AstraZeneca (UK) | ChAdOx1 (AZS1222) | EMA/ MFDS KOREA/ Japan MHLW/PMDA/ Australia TGA | Non ReplicatingViral vector |
| 3 | Serum Institute of India (India) | Covishield (ChAdOx1_nCoV-19) | DCGI | Non Replicating Viral Vector |
| 4 | Johnson &Johnson (US) | Ad26.CoV2.S | EMA | Non ReplicatingViral vector |
| 5 | Moderna (US) | mRNA-1273 | EMA/USFDA | mRNA |
| 6 | Sinopharm Beijing (China) | BBIBP-CorV | NMPA | Inactivated virus (Vero Cells) |
| 7 | Sinovac (China) | SARS-CoV-2 Vaccine | NMPA | Inactivated virus (Vero Cell) |

- **23** Vaccines Approved by at Least One Country

| Vaccine Type | mRNA | Non Replicating Viral vector | Inactivated virus | Protein Subunit | DNA | Total |
|---|---|---|---|---|---|---|
| In Use | 3 | 6 | 8 | 5 | 1 | **23** |

Source: https://covid19.trackvaccines.org/vaccines/ （Last Updated 19 Oct 2021）

- Vaccination against COVID-19 has now started in **217** locations

  (Source: Our World in Data.Last Updated 18 Oct 2021)

| Location | Doses given | Fully vaccinated (% of population) | At least 1 dose (% of population) |
|---|---|---|---|
| Worldwide | 6.7 billion | 2.86 billion (36.26%) | 3.76 billion (47.76%) |

About this data:

a: This data changes rapidly and might not reflect doses still being reported. It may differ from other sites & sources.

b: Where data for full vaccinations is available, it shows how many people have received at least 1 dose and how many people have been fully vaccinated (which may require more than 1 dose).Where data for full vaccinations isn't available, the data shows the total number of vaccine doses given to people. Since some vaccines require more than 1 dose, the number of fully vaccinated people is likely lower.

c: It only has full vaccination totals in some locations.









## 2. Vaccine effectiveness against symptomatic infection for Alpha and Delta variants

| Vaccine Status | Vaccine Effectiveness | |
|---|---|---|
| | **Alpha** | **Delta** |
| 1 Dose (BNT162b2 or ChAdOx1 nCoV-19) | 48.7% (95%CI: 45.5-51.7%)[1]<br>66%(BNT162b2)[4]<br>64% (ChAdOx1)[4] | 30.7% (95%CI: 25.2-35.7%)[1]<br>56%(BNT162b2)[4]<br>67%(ChAdOx1)[4] |
| 1 Dose (mRNA-1273) | 83%[4] | 72%[4] |
| 1 Dose(Sinopharm or Sinovac) | Unknown | 13.8%,(95%CI: -60.2-54.8%)[3] |
| 2 Doses (BNT162b2) | 93.7% (95%CI: 91.6-95.3)[1]<br>76% (95%CI: 69-81%)[2]<br>89% [4] | 88% (95%CI: 85.3-90.1%)1<br>42% (95% CI: 13-62%)2<br>87%[4] |
| 2 Doses (ChAdOx1 nCoV-19) | 74.5% (95%CI: 68.4-79.4%)[1] | 67.0% (95%CI: 61.3-71.8%)[1] |
| 2 Doses (mRNA-1273) | 86%, (95%CI: 81-90.6%)[2] | 76%, (95% CI: 58-87%)[2] |
| 2 Doses(Sinopharm or Sinovac) | Unknown | 59.0%, (95%CI: 16.0-81.6%)[3] |

References:


1) Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
2) Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
3) Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study
4) Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada

### 3. Latest Relevant Articles

- Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
- Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study
- Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: a cohort study using OpenSAFELY
- Time-varying effectiveness of the mRNA-1273, BNT162b2 and Ad26.COV2.S vaccines against SARS-CoV-2 infections and COVID-19 hospitalizations and deaths: an analysis based on observational data from Puerto Rico
- COVID-19 Vaccine Effectiveness by Product and Timing in New York State

### 4. Other Information

- F.D.A. to Allow ‘Mix and Match’ Approach for Covid Booster Shots
- CDC: Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021